Table 2.
Subgroup analysis based on postoperative weight gain of <5% vs. ≥5%
| Weight gain < 5% (n = 31) | Weight gain ≥ 5% (n = 55) | P -value | |
|---|---|---|---|
| BMI category at presentation, N (%) n = 85 | |||
| Obese | 15 (48) | 20 (37) | 0.5 |
| Overweight | 11 (34) | 21 (39) | |
| Normal weight | 5 (16) | 13 (24) | |
| Mean tumor size (SD), cm n = 82 | 2.4 ± 0.2 (n = 30) | 2.8 ± 0.1 (n = 52) | 0.5 |
| Histological subtype, N (%) n = 83 | |||
| Adamantinomatous | 24 (83) | 47 (87) | 0.6 |
| Papillary | 5 (17) | 7 (13) | |
| Gross total resection, N (%), (n = 31) | 17 (57) | 24 (43) | 0.6^ |
| Use of radiotherapy, N (%) n = 86 | 12 (28) | 31 (72) | 0.1 |
| Grade of hypothalamic injury postoperative, N (%) n = 82 | |||
| Grade 0 | 17 (59) | 25 (47) | 0.5 |
| Grade 1 | 5 (17) | 15 (28) | |
| Grade 2 | 7 (24) | 13 (25) | |
| Anterior Pituitary Hormone at last follow-up, N (%) | |||
| ACTH deficiency (n = 85) | 25 (81) | 40 (74) | 0.5 |
| TSH deficiency (n = 85) | 26 (84) | 43 (80) | 0.6 |
| Gonadotropin deficiency n = 74 | 22 (81) | 39 (83) | 0.9 |
| Hyperprolactinemia n = 59 | 11 (55) | 18 (46) | 0.5 |
| GH deficiency n = 41 | 11 (65) | 14 (58) | 0.7 |
| ≥3 Anterior Pituitary Deficiencies n = 77 | 22 (79) | 33 (67) | 0.3 |
| GH deficiency, not on replacement at last follow-up, N (%) n = 25 | 6 (55) | 5 (36) | 0.3 |
| Diabetes insipidus at last follow-up, N (%) n = 85 | 22 (71) | 32 (60) | 0.3 |
| Metabolic parameters at last follow-up, N (%) | |||
| Hypertension | 11 (35) | 22 (40) | 0.6 |
| Glycemic disturbance n = 86 | 11 (35) | 18 (33) | 0.8 |
| Dyslipidemia, n = 86 | 18 (58) | 19 (35) | 0 |
ACTH adrenocorticotrophic hormone, BMI body mass index, GH growth hormone, TSH thyroid-stimulating hormone, SD standard deviation
^Fischer’s exact test